Clinical Trials Using Dual ALK/EGFR Inhibitor AP26113
Clinical trials are research studies that involve people. The clinical trials on this list are studying Dual ALK/EGFR Inhibitor AP26113. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Biomarker / ALK Inhibitor Combinations in Treating Patients with Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)
This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker / ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether a combination of biomarker / ALK inhibitors or chemotherapy may work better in treating patients with ALK positive non-squamous non-small cell lung cancer.
Location: 341 locations
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
Location: 5 locations
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criteria in solid tumors (Response Evaluation Criteria in Solid Tumors [RECIST]), in participants with ALK+ locally advanced or metastatic NSCLC whose disease has progressed on therapy with alectinib or ceritinib.
Location: 3 locations
Brigatinib in Treating Patients with ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1 gene alterations and solid cancers that have spread to nearby tissue and lymph nodes or other places in the body. Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Brigatinib in Treating Patients with Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
This phase II trial studies how well brigatinib works in treating patients with ALK-positive anaplastic large cell lymphoma that has come back after previous treatment or does not respond to treatment. Brigatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Local Consolidative Therapy and Brigatinib in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer
This early phase I trial studies the side effects and how well local consolidative therapy (LCT) and brigatinib works in treating patients with non-small cell lung cancer that is stage IV or has come back. Giving LCT, such as surgery and / or radiation, after initial treatment may kill any remaining tumor cells. Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving LCT and brigatinib may work better in treating patients with non-small cell lung cancer.
Location: M D Anderson Cancer Center, Houston, Texas
An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Participants Who Have Progressed on Crizotinib
The purpose of this study is to compare the efficacy of brigatinib versus alectinib in participants with anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have progressed on crizotinib as evidenced by progression free survival as assessed by a blinded independent review committee (BIRC) utilizing response evaluation criteria in solid tumors (RECIST) v1.1.
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Brigatinib and Binimetinib in Treating Patients with Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of brigatinib and binimetinib in treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: UCSF Medical Center-Mount Zion, San Francisco, California